Advanced Donor Age Alone Is Not a Risk Factor for Graft Survival in Kidney Transplantation

2011 ◽  
Vol 43 (5) ◽  
pp. 1537-1543 ◽  
Author(s):  
T. Karatzas ◽  
J. Bokos ◽  
A. Katsargyris ◽  
K. Diles ◽  
G. Sotirchos ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplantation ◽  
Graft Survival ◽  
Donor Age

scholarly journals US deceased kidney transplantation: Estimated GFR, donor age and KDPI association with graft survival

2021 ◽  
pp. 100980
Author(s):  
Timothy L. Pruett ◽  
Gabriel R. Vece ◽  
Robert J. Carrico ◽  
David K. Klassen
Keyword(s):  
Kidney Transplantation ◽  
Graft Survival ◽  
Donor Age ◽  
Estimated Gfr

scholarly journals Attitudes to Medication after Kidney Transplantation and Their Association with Medication Adherence and Graft Survival: A 2-Year Follow-Up Study

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Mirjam Tielen ◽  
Job van Exel ◽  
Mirjam Laging ◽  
Denise K. Beck ◽  
Roshni Khemai ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplantation ◽  
Medication Adherence ◽  
Graft Survival ◽  
Renal Transplant Recipients ◽  
Kidney Recipients ◽  
Immunosuppressive Medications ◽  
Study Results ◽  
Intrapatient Variability

Background. Nonadherence to medication is a common problem after kidney transplantation. The aim of this study was to explore attitudes towards medication, adherence, and the relationship with clinical outcomes.Method. Kidney recipients participated in a Q-methodological study 6 weeks after transplantation. As a measure of medication adherence, respondents completed the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS©-interview). Moreover, the intrapatient variability in the pharmacokinetics of tacrolimus was calculated, which measures stability of drug intake. Data on graft survival was retrieved from patient records up to 2 years after transplantation.Results. 113 renal transplant recipients (19–75 years old) participated in the study. Results revealed three attitudes towards medication adherence—attitude 1: “confident and accurate,” attitude 2: “concerned and vigilant,” and attitude 3: “appearance oriented and assertive.” We found association of attitudes with intrapatient variability in pharmacokinetics of tacrolimus, but not with self-reported nonadherence or graft survival. However, self-reported nonadherence immediately after transplantation was associated with lower two-year graft survival.Conclusion. These preliminary findings suggest that nonadherence shortly after kidney transplantation may be a risk factor for lower graft survival in the years to follow. The attitudes to medication were not a risk factor.

scholarly journals Minimal Proteinuria One Year after Transplant is a Risk Factor for Graft Survival in Kidney Transplantation

2009 ◽  
Vol 24 (Suppl 1) ◽  
pp. S129 ◽  
Author(s):  
Na Ree Kang ◽  
Jung Eun Lee ◽  
Wooseong Huh ◽  
Sung Joo Kim ◽  
Yoon-Goo Kim ◽  
...  
Keyword(s):  
Risk Factor ◽  
Kidney Transplantation ◽  
Graft Survival ◽  
One Year

Impact of donor age on long-term graft survival in living donor kidney transplantation

1998 ◽  
Vol 30 (7) ◽  
pp. 3118-3119 ◽  
Author(s):  
A Kanematsu ◽  
K Tanabe ◽  
N Ishikawa ◽  
T Tokumoto ◽  
S Huchinoue ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Donor Age ◽  
Donor Kidney ◽  
Living Donor Kidney Transplantation ◽  
Donor Kidney Transplantation ◽  
Living Donor Kidney

scholarly journals Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates

2017 ◽  
Vol 1 (24) ◽  
pp. 2115-2119 ◽  
Author(s):  
Jean Kwun ◽  
Christopher Burghuber ◽  
Miriam Manook ◽  
Brian Ezekian ◽  
Jaeberm Park ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Graft Survival ◽  
Nonhuman Primates ◽  
Proteasome Inhibition ◽  
Costimulation Blockade ◽  
Specific Antibodies ◽  
Key Points ◽  
Donor Specific Antibodies

Key Points Targeting both PCs and GC response reduces donor-specific antibodies and prolongs graft survival in sensitized NHP kidney transplantation.

scholarly journals Safety and effectiveness of kidney transplantation using a donation after brain death donor with acute kidney injury: a retrospective cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kyeong Deok Kim ◽  
Kyo Won Lee ◽  
Sang Jin Kim ◽  
Okjoo Lee ◽  
Manuel Lim ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Kidney Transplantation ◽  
Brain Death ◽  
Graft Survival ◽  
Low Dose ◽  
Kidney Injury ◽  
Induction Agent ◽  
Donor Pool ◽  
Donation After Brain Death

AbstractThe use of kidneys from donation after brain death (DBD) donors with acute kidney injury (AKI) is a strategy to expand the donor pool. The aim of this study was to evaluate how kidney transplantation (KT) from a donor with AKI affects long-term graft survival in various situations. All patients who underwent KT from DBD donors between June 2003 and April 2016 were retrospectively reviewed. The KDIGO (Kidney Disease: Improving Global Outcomes) criteria were used to classify donor AKI. The cohort included 376 donors (no AKI group, n = 117 [31.1%]; AKI group n = 259 [68.9%]). Death-censored graft survival was similar according to the presence of AKI, AKI severity, and the AKI trend (p = 0.929, p = 0.077, and p = 0.658, respectively). Patients whose donors had AKI who received using low dose (1.5 mg/kg for three days) rabbit anti-thymocyte globulin (r-ATG) as the induction agent had significantly superior death-censored graft survival compared with patients in that group who received basiliximab (p = 0.039). AKI in DBD donors did not affect long-term death-censored graft survival. Low-dose r-ATG may be considered as an induction immunosuppression in recipients receiving kidneys with AKI because it showed better graft survival than basiliximab.

scholarly journals Impact of Early Pancreatic Graft Loss on Outcome after Simultaneous Pancreas–Kidney Transplantation (SPKT)—A Landmark Analysis

2021 ◽  
Vol 10 (15) ◽  
pp. 3237
Author(s):  
Lukas Johannes Lehner ◽  
Robert Öllinger ◽  
Brigitta Globke ◽  
Marcel G. Naik ◽  
Klemens Budde ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Graft Survival ◽  
Graft Loss ◽  
Type I ◽  
Kidney Graft ◽  
Landmark Analysis ◽  
Pancreas Kidney Transplantation ◽  
Simultaneous Pancreas Kidney ◽  
Simultaneous Pancreas Kidney Transplantation ◽  
Pancreas Graft

(1) Background: Simultaneous pancreas–kidney transplantation (SPKT) is a standard therapeutic option for patients with diabetes mellitus type I and kidney failure. Early pancreas allograft failure is a complication potentially associated with worse outcomes. (2) Methods: We performed a landmark analysis to assess the impact of early pancreas graft loss within 3 months on mortality and kidney graft survival over 10 years. This retrospective single-center study included 114 adult patients who underwent an SPKT between 2005 and 2018. (3) Results: Pancreas graft survival rate was 85.1% at 3 months. The main causes of early pancreas graft loss were thrombosis (6.1%), necrosis (2.6%), and pancreatitis (2.6%). Early pancreas graft loss was not associated with reduced patient survival (p = 0.168) or major adverse cerebral or cardiovascular events over 10 years (p = 0.741) compared to patients with functioning pancreas, after 3 months. Moreover, kidney graft function (p = 0.494) and survival (p = 0.461) were not significantly influenced by early pancreas graft loss. (4) Conclusion: In this study, using the landmark analysis technique, early pancreas graft loss within 3 months did not significantly impact patient or kidney graft survival over 10 years.

Sign in / Sign up

Export Citation Format

Share Document